Reviewing 23 years of clinical experience, we report here, for the first time, long-term OS outcomes in 259 consecutive Binet A stage patients in both eras of chemoimmunotherapy and targeted agents in the context of CLL-IPI risk stratification, elevated B2M plasma levels, and concurrent CKD. This evidence concerns the gene B2M and chronic kidney disease.